A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms KEYNOTE-011
- Sponsors Merck Sharp & Dohme
- 09 Apr 2019 Planned primary completion date changed from 1 Jun 2018 to 30 Jun 2020.
- 09 Apr 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
- 07 May 2018 Planned End Date changed from 15 Dec 2019 to 17 Apr 2020.